Cargando…

mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucia...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yingqi, Hou, Chen, Li, Yonghao, Zheng, Kang, Wang, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813741/
https://www.ncbi.nlm.nih.gov/pubmed/35126377
http://dx.doi.org/10.3389/fimmu.2021.821538
_version_ 1784644927344345088
author Jin, Yingqi
Hou, Chen
Li, Yonghao
Zheng, Kang
Wang, Chuan
author_facet Jin, Yingqi
Hou, Chen
Li, Yonghao
Zheng, Kang
Wang, Chuan
author_sort Jin, Yingqi
collection PubMed
description Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies.
format Online
Article
Text
id pubmed-8813741
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88137412022-02-05 mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2 Jin, Yingqi Hou, Chen Li, Yonghao Zheng, Kang Wang, Chuan Front Immunol Immunology Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies. Frontiers Media S.A. 2022-01-21 /pmc/articles/PMC8813741/ /pubmed/35126377 http://dx.doi.org/10.3389/fimmu.2021.821538 Text en Copyright © 2022 Jin, Hou, Li, Zheng and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jin, Yingqi
Hou, Chen
Li, Yonghao
Zheng, Kang
Wang, Chuan
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
title mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
title_full mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
title_fullStr mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
title_full_unstemmed mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
title_short mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
title_sort mrna vaccine: how to meet the challenge of sars-cov-2
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813741/
https://www.ncbi.nlm.nih.gov/pubmed/35126377
http://dx.doi.org/10.3389/fimmu.2021.821538
work_keys_str_mv AT jinyingqi mrnavaccinehowtomeetthechallengeofsarscov2
AT houchen mrnavaccinehowtomeetthechallengeofsarscov2
AT liyonghao mrnavaccinehowtomeetthechallengeofsarscov2
AT zhengkang mrnavaccinehowtomeetthechallengeofsarscov2
AT wangchuan mrnavaccinehowtomeetthechallengeofsarscov2